Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma-Reference-Cited by-同舟云学术

Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma

Published:2023-12-01 Issue:6 Volume:25 Page:288-299
ISSN:2152-4971
Container-title:Cellular Reprogramming
language:en
Short-container-title:Cellular Reprogramming

Author:

Karg Margarete M.¹,Lu Yuancheng Ryan²³^ORCID,Refaian Nasrin¹,Cameron James³,Hoffmann Emma¹,Hoppe Cindy¹,Shirahama Shintaro¹,Shah Madhura¹,Krasniqi Drenushe¹,Krishnan Anitha¹,Shrestha Maleeka¹,Guo Yinjie¹,Cermak Jennifer M.⁴,Walthier Michel⁴,Broniowska Kasia⁴,Rosenzweig-Lipson Sharon⁴,Gregory-Ksander Meredith¹,Sinclair David A.²,Ksander Bruce R.¹

Affiliation:

1. Schepens Eye Research Institute of Mass Eye & Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA.

2. Paul F. Glenn Center for Biology of Aging Research, Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts, USA.

3. Whitehead Institute for Biomedical Research, Department of Biology, MIT, Cambridge, Massachusetts, USA.

4. Life Biosciences LLC, Boston, Massachusetts, USA.

Publisher

Mary Ann Liebert Inc

Subject

Cell Biology,Developmental Biology,Biotechnology

Link

https://www.liebertpub.com/doi/pdf/10.1089/cell.2023.0074

Reference35 articles.

1. Reprogramming in vivo produces teratomas and iPS cells with totipotency features

2. A single short reprogramming early in life initiates and propagates an epigenetically related mechanism improving fitness and promoting an increased healthy lifespan

3. Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future